FDA approves olaparib first-line maintenance therapy for ovarian cancer


  • Deepa Koli
  • Oncology drug update
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The FDA has approved olaparib maintenance treatment in adult patients with deleterious or suspected deleterious germline/somatic BRCA+ advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
  • Recommended dose is 300 mg twice daily, with or without food.
  • The FDA also approved ­­­­BRACAnalysis CDx test to identify patients with germline BRCA-mutation eligible for olaparib.

Why this matters

  • Advanced ovarian cancer has poor prognosis.

Key highlights

  • Approval was based on the double-blind, placebo-controlled SOLO-1 trial.
  • 391 patients were randomly assigned 2:1 to receive olaparib (n=260) or placebo (n=131).
  • Olaparib was associated with significantly longer investigator-assessed median PFS (not reached vs 13.8 months; HR, 0.30; P<.0001 vs placebo.>
  • OS data were not mature.
  • Most common adverse events (≥10%) with olaparib were nausea, fatigue, abdominal pain, vomiting, anemia, diarrhea, upper respiratory tract infection/influenza/nasopharyngitis/bronchitis, constipation, dysgeusia, decreased appetite, dizziness, neutropenia, dyspepsia, dyspnea, urinary tract infection, leukopenia, thrombocytopenia, and stomatitis.
  • Deleterious germline BRCA mutation was identified using ­­­­BRACAnalysis CDx test in SOLO-1.

Prescribing Information, click  here .    

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit